Phase 3 topline results from COAST, expected in early Q2 CY2025; Phase 3 topline results from ShORe, expected in mid-CY2025; BLA submission in 1H CY2026
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPT:
- Optimistic Buy Rating for Opthea Limited Driven by Promising Phase 3 Trials and Innovative AMD Treatment
- Opthea completes drug product PPQ campaign
- Optimistic Outlook and Buy Rating for Opthea Limited Amid Promising Phase 3 Trials and Strong Financial Position
- Opthea completes COAST final week 52 patient visit
- Opthea Completes Key Phase 3 Trial Milestone in Wet AMD Treatment